MCRB compared with SANA: revenue, margins and what each company keeps, and the suppliers and customers both name

MCRBSeres Therapeutics, Inc.

Mkt capRevenueRevenue

SANASana Biotechnology, Inc.

Mkt capRevenueRevenue

Compare

MCRBSeres Therapeutics, Inc.

SANASana Biotechnology, Inc.

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Earnings history

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

Earnings history

last 4 reports each · paired by recencyMethod ›

MCRB1 of 4 reports

0 of 1at or beyond implied

Reportimpliedrealized× implied

Q2 FY26±41.0%▼−4.67%×0.11

SANA

0 of 4at or beyond implied

Reportimpliedrealized× implied

Q2 FY26±28.3%▲+4.99%×0.18

May 12 '26±29.1%▼−8.43%×0.29

= impliedMCRB realized, solidSANA realized, hatchedOne scale, both sides: full bar = 42%× = |realized| ÷ impliedSource: market data

Q1 FY26

±23.8%

▼−2.80%

×0.12

Q3 FY25±28.0%▲+0.99%×0.04

MCRBSeres Therapeutics, Inc.

1.76▼−9.72%· post 1.76

Mkt cap$17.6MRevenue$736,000Q2 FY26

SANASana Biotechnology, Inc.

2.56▼−5.88%· post 2.56

ClosedOct 30 '26

Mkt cap$769.4MRevenue—

Compare

ClosedOct 30 '26

MCRBSeres Therapeutics, Inc.

SANASana Biotechnology, Inc.

1.76▼−9.72%post 1.76

Price

2.56▼−5.88%post 2.56

$17.6M

Mkt cap

$769.4M

Q2 FY26$736,000

Revenue

—

MCRB1.76▼−9.72%vsSANA2.56▼−5.88%ClosedOct 30 '26